Deutetrabenazine, (R,S)-rel- | 2244238-16-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: Deutetrabenazine, (R,S)-rel-
• 英文别名: (3S,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
• CAS: 2244238-16-0
• 化学式: C19H27NO3
• 分子量: 323.5
• InChiKey: MKJIEFSOBYUXJB-XZNUEWKKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
  申请人：AUSPEX PHARMACEUTICALS, INC.

  公开号：US11033540B2

  公开（公告）日：2021-06-15

  The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

  本发明涉及包含苯并喹啉化合物的新药物组合物，以及在受试者体内抑制膀胱单胺转运体2（VMAT2）活性以治疗慢性过度运动障碍的方法。
• FORMULATIONS PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
  申请人：Auspex Pharmaceuticals, Inc.

  公开号：US20140336386A1

  公开（公告）日：2014-11-13

  The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
• FORMULATIONS AND PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
  申请人：Auspex Pharmaceuticals, Inc.

  公开号：US20150004231A1

  公开（公告）日：2015-01-01

  The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
• US20140341994A1
  申请人：——

  公开号：US20140341994A1

  公开（公告）日：2014-11-20
• FORMULATIONS and PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
  申请人：Auspex Pharmaceuticals, Inc.

  公开号：US20160235733A1

  公开（公告）日：2016-08-18

  The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.